In part 1 of a 2-part series, neuro-endocrinologist Andrew G. Herzog, MD, CM, discusses the potential pathophysiology of catamenial epilepsy, why research is limited, and how to improve the standard of care.
Researchers sought to report the efficacy and safety data of adjunctive cenobamate in patients with uncontrolled focal seizures from a long-term open-label phase 3 study.
Researchers sought to compare the brain morphometry of pediatric patients with epilepsy with myoclonic atonic seizure to healthy individuals years after epilepsy onset, and to correlate it to disease severity and cognitive findings.
Neurava, an Indiana startup developing a wearable device to monitor the potential risk for sudden, unexpected death in epilepsy (SUDEP), receives funding to complete the final prototype.
Researchers sought to quantify and model the putative risk for cardiovascular disease related to the use of enzyme-inducing antiseizure medications in adult patients with epilepsy.
Researchers assessed the potential clinical benefits of transcutaneous auricular vagus nerve stimulation and wanted to determine the adaptation, compliance, and usability of the device for patients with drug-resistant epilepsy.
Researchers determined the effect of low-dose levetiracetam, an antiseizure drug, on cognitive function in patients with Alzheimer disease with epileptiform activity.
